|
Retargetable and Metabolically Tunable CAR Cell Platforms for Durable, Antigen‑Specific Cancer Therapy
SHORT DESCRIPTION
A modular immunotherapy platform that combines hapten‑redirectable chimeric antigen receptor (CAR) constructs with itaconate‑programmed, memory‑like immune cells to deliver safer, more durable, and tunable antigen‑specific responses across hematologic and solid tumors.
NU TECH ID
NU 2023-021, NU 2024-077
INVENTORS
Ashima...
Published: 6/10/2026
|
Updated: 6/10/2026
|
Inventor(s):
Keywords(s): Autoimmune disease, Cancer Treatment, Cancer/Oncology, Cell therapy, Immunology, Immunotherapy, Inflammation, Leukemia, Lymphoma, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Use of Nucleotide Synthesis Inhibitors for Targeted Therapy in MLL3/4 COMPASS Mutant Cancer
NU 2022-053
INVENTORS
Ali Shilatifard (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
Zibo Zhao (Feinberg School of Medicine, Department of Biochemistry and Molecular Genetics)*
SHORT DESCRIPTION
A therapeutic platform that targets MLL3/4 COMPASS mutant cancers by using nucleotide synthesis inhibitors to disrupt...
Published: 5/26/2026
|
Updated: 4/29/2026
|
Inventor(s):
Keywords(s): Bladder cancer, Breast cancer, Cancer/Oncology, Colon cancer, Gastric cancer, Leukemia, Lung cancer, Lymphoma, Prostate cancer, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION
Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy.
INVENTORS
Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)*
Jindan...
Published: 5/6/2026
|
Updated: 3/5/2026
|
Inventor(s):
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|
|
Therapy for T-Cell Lymphoma
NU2022-104
INVENTORS
Jaehyuk Choi*
Jay Daniels
Jurgen Ruland
Tim Wartweig
SHORT DESCRIPTION
Targeting PD-1 related mechanisms for treatment of aggressive T-Cell lymphomas
BACKGROUND
T-cell non-Hodgkin lymphomas (T-NHLs) are highly aggressive cancers that can be resistant to chemotherapies. The molecular pathogenesis of these cancers remains...
Published: 12/15/2025
|
Updated: 5/14/2024
|
Inventor(s):
Keywords(s): Cancer/Oncology, Lymphoma, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
|